Please assess the completion status of the following clinical trial:

Trial Title: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who received a prescription for a SGLT2 inhibitor or DPP-4 inhibitor on or after the date of the first dispensation of a SGLT2 inhibitor at each site and on or before June 30, 2018 (or latest date of data availability at each site)~Exclusion Criteria:~* Patients who received both a first prescription for a SGLT2 inhibitor and a DPP-4 inhibitor on the same date~* Patients with missing sex~* Patients aged less than 18 years at cohort entry date (\<19 years in Alberta and \<66 years in Ontario)~* Patients with less than 365 days of healthcare coverage prior to cohort entry date~* Patients with date inconsistencies or no follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors (Type: None): Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors (Type: None): Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.

Based on this trial design, predict the completion outcome and termination type (if applicable).